PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
Mesa R. et al, (2015), HAEMATOLOGICA, 100, 336 - 337
PERSIST-1: A PHASE III STUDY OF PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT) IN PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (PPV-MF) OR POST-ESSENTIAL THROMBOCYTHEMIA MF (PET-MF)
Harrison C. et al, (2015), HAEMATOLOGICA, 100, 103 - 103
PROSPECTIVE ISOLATION OF NOVEL POPULATIONS OF MEGAKARYOCYTE-AND ERYTHROID-PRIMED MEGAKARYOCYTE-ERYTHROID PROGENITORS DEMONSTRATES MEGAKARYOCYTE-BIASED LINEAGE COMMITMENT IN PRIMARY MYELOFIBROSIS
Psaila B. et al, (2015), HAEMATOLOGICA, 100, 97 - 97
The next steps in improving the outcomes of advanced ovarian cancer.
Openshaw MR. et al, (2015), Womens Health (Lond), 11, 355 - 367
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas AL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
Olszanski AJ. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Van Schaeybroeck S. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Wainberg ZA. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.
Clark LL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Long-term outcomes of autologous stem cell transplantation for peripheral T-cell lymphomas across the Thames Valley (1997-2012).
Sims MC. et al, (2015), Br J Haematol, 169, 452 - 455
Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.
Lord SR. et al, (2015), J Natl Cancer Inst Monogr, 2015, 81 - 86
Phase I study of the PI3K alpha inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
Janku F. et al, (2015), CANCER RESEARCH, 75
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J. et al, (2015), BJOG, 122, 843 - 849
B-cell depletion in immune thrombocytopenia.
Psaila B. and Cooper N., (2015), Lancet, 385, 1599 - 1601
Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs.
Iskander D. et al, (2015), Blood, 125, 2553 - 2557
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.
Tapper W. et al, (2015), Nat Commun, 6
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Findlay JM. et al, (2015), Ann Oncol, 26, 624 - 644
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Suttle AB. et al, (2015), J Clin Pharmacol, 55, 392 - 400
Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial
Scherber R. et al, (2015), BRITISH JOURNAL OF HAEMATOLOGY, 169, 81 - 81
Decision theory and cost-benefit analysis of re-staging oesophageal cancer after neoadjuvant chemotherapy with PET-CT rather than CT
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 41 - 41